EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects



Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects



Proceedings of the National Academy of Sciences of the United States of America 98(23): 13288-13293



The risks and benefits of structured treatment interruption (STI) in HIV-1-infected subjects are not fully understood. A pilot study was performed to compare STI with continuous highly active antiretroviral therapy (HAART) in chronic HIV-1-infected subjects with HIV-1 plasma RNA levels (VL) <400 copies per ml and CD4(+) T cells >400 per microl. CD4(+) T cells, VL, HIV-1-specific neutralizing antibodies, and IFN-gamma-producing HIV-1-specific CD8(+) and CD4(+) T cells were measured in all subjects. STIs of 1-month duration separated by 1 month of HAART, before a final 3-month STI, resulted in augmented CD8(+) T cell responses in all eight STI subjects (P = 0.003), maintained while on HAART up to 22 weeks after STI, and augmented neutralization titers to autologous HIV-1 isolate in one of eight subjects. However, significant decline of CD4(+) T cell count from pre-STI level, and VL rebound to pre-HAART baseline, occurred during STI (P = 0.001 and 0.34, respectively). CD4(+) T cell counts were regained on return to HAART. Control subjects (n = 4) maintained VL <400 copies per ml and stable CD4(+) T cell counts, and showed no enhancement of antiviral CD8(+) T cell responses. Despite increases in antiviral immunity, no control of VL was observed. Future studies of STI should proceed with caution.

(PDF emailed within 0-6 h: $19.90)

Accession: 003946741

Download citation: RISBibTeXText

PMID: 11687611

DOI: 10.1073/pnas.221452198



Related references

Influence of prior structured treatment interruptions on the length of time without antiretroviral treatment in chronically HIV-infected subjects. Aids Research and Human Retroviruses 20(12): 1283-1288, 2005

Determinants of virologic and immunologic outcomes in chronically HIV-infected subjects undergoing repeated treatment interruptions: the Istituto Superiore di Sanita-Pulsed Antiretroviral Therapy (ISS-PART) study. Journal of Acquired Immune Deficiency Syndromes 46(1): 39-47, 2007

Viral evolution during structured treatment interruptions in chronically human immunodeficiency virus-infected individuals. Journal of Virology 76(23): 12344-12348, December, 2002

Low Non-structured Antiretroviral Therapy Interruptions in HIV-Infected Persons Who Inject Drugs Receiving Multidisciplinary Comprehensive HIV Care at an Outpatient Drug Abuse Treatment Center. Aids and Behavior 20(5): 1068-1075, 2017

Structured treatment interruptions in antiretroviral management of HIV-1. Current Opinion in Infectious Diseases 14(1): 29-37, 2002

Structured interruptions in antiretroviral treatment: a new therapeutic strategy?. Enfermedades Infecciosas Y Microbiologia Clinica 20(8): 373-375, 2002

Mutations Related to Antiretroviral Resistance Identified by Ultra-Deep Sequencing in HIV-1 Infected Children under Structured Interruptions of HAART. Plos One 11(1): E0147591-E0147591, 2016

Immunovirologic consequences and safety of short, non-structured interruptions of successful antiretroviral treatment. Journal of Infection 54(2): 159-166, 2006

Managing antiretroviral therapy: changing regimens, resistance testing, and the risks from structured treatment interruptions. Journal of Infectious Diseases 197 Suppl 3: S261-S271, 2008

Aseptic meningitis and acute HIV syndrome after interruption of antiretroviral therapy: implications for structured treatment interruptions. Aids 17(14): 2145-2146, 2003

CD4+ T-cell-guided structured treatment interruptions of antiretroviral therapy in HIV disease: projecting beyond clinical trials. Antiviral Therapy 15(3): 351-361, 2010

Development of HIV with drug resistance after CD4 cell count-guided structured treatment interruptions in patients treated with highly active antiretroviral therapy after dual-nucleoside analogue treatment. Clinical Infectious Diseases 40(5): 728-734, 2005

Structured interruptions of highly active antiretroviral therapy in cycles of 4 weeks off/12 weeks on therapy in children having a chronically undetectable viral load cause progressively smaller viral rebounds. International Journal of Infectious Diseases 14(1): E34-E40, 2010

Long-term consequences of treatment interruptions in chronically HIV-1-infected patients. European Journal of Medical Research 10(2): 56-62, 2005

Modifications of residual viraemia in human immunodeficiency virus-1-infected subjects undergoing repeated highly active antiretroviral therapy interruptions. Journal of Medical Microbiology 58(Pt 1): 121-124, 2009